101 related articles for article (PubMed ID: 26898708)
1. Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Bosse RC; Wasserstrom B; Meacham A; Wise E; Drusbosky L; Walter GA; Chaplin DJ; Siemann DW; Purich DL; Cogle CR
Exp Hematol; 2016 May; 44(5):363-377.e5. PubMed ID: 26898708
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Drusbosky L; Gars E; Trujillo A; McGee C; Meacham A; Wise E; Scott EW; Cogle CR
Leuk Res; 2015 Sep; 39(9):984-9. PubMed ID: 26189107
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Pan B; Xu K; Yokoyama A
Cancer Sci; 2017 Apr; 108(4):685-695. PubMed ID: 28107581
[TBL] [Abstract][Full Text] [Related]
5. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
6. A novel strategy for isolation of mice bone marrow endothelial cells (BMECs).
Smith AO; Adzraku SY; Ju W; Qiao J; Xu K; Zeng L
Stem Cell Res Ther; 2021 May; 12(1):267. PubMed ID: 33941266
[TBL] [Abstract][Full Text] [Related]
7. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
8. Leukemia regression by vascular disruption and antiangiogenic therapy.
Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow fibroblast exposure to the inflammatory cytokines tumor necrosis factor-alpha and interferon-gamma increases adhesion of acute myeloid leukemia cells and alters the adhesive mechanism.
Bendall LJ; Kortlepel K; Gottlieb DJ
Exp Hematol; 1997 Feb; 25(2):132-9. PubMed ID: 9015213
[TBL] [Abstract][Full Text] [Related]
10. Low proportion of G0-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia.
Kamikubo KH; Ogata K; An E; Dan K
Int J Hematol; 2000 Apr; 71(3):249-55. PubMed ID: 10846830
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in the vascular niche.
Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
13. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers.
Henschler R; Göttig S; Junghahn I; Bug G; Seifried E; Müller AM; Fichtner I
Leuk Res; 2005 Oct; 29(10):1191-9. PubMed ID: 15941586
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
[TBL] [Abstract][Full Text] [Related]
16. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
Konopleva M; Konoplev S; Hu W; Zaritskey AY; Afanasiev BV; Andreeff M
Leukemia; 2002 Sep; 16(9):1713-24. PubMed ID: 12200686
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
Nishioka C; Ikezoe T; Yokoyama A
Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
[TBL] [Abstract][Full Text] [Related]
18. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia.
Litwin C; Leong KG; Zapf R; Sutherland H; Naiman SC; Karsan A
Am J Hematol; 2002 May; 70(1):22-30. PubMed ID: 11994978
[TBL] [Abstract][Full Text] [Related]
19. Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Liesveld JL; Rosell KE; Lu C; Bechelli J; Phillips G; Lancet JE; Abboud CN
Hematology; 2005 Dec; 10(6):483-94. PubMed ID: 16321813
[TBL] [Abstract][Full Text] [Related]
20. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Reikvam H; Hatfield KJ; Oyan AM; Kalland KH; Kittang AO; Bruserud O
Eur J Haematol; 2010 Mar; 84(3):239-51. PubMed ID: 19922462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
